Usefulness of $^{18}$F-fluorodeoxyglucose-positron emission tomography/computed tomography in primary cystadenocarcinoma of the mesentery: a case report

Yuto Hozaka1*, Yuko Mataki1, Hiroshi Kurahara1, Kiyonori Tanoue1, Tetsuya Idichi1, Yota Kawasaki1, Satoshi Iino1, Pramod Nepal1, Takaaki Arigami1, Kosei Maemura1, Hirotsugu Noguchi2, Hiroyuki Shinchi3, Akihide Tanimoto2, Shoji Natsugoe1 and Takao Ohtsuka1

Abstract

Background: Mesenteric cysts have various histological forms, including mesenteric cystadenomas and borderline cystic neoplasms. Primary cystadenocarcinoma of the mesentery is extremely rare; therefore, the clinical and radiological features of this tumor have not been fully elucidated.

Case presentation: A 50-year-old Japanese woman had a complaint of a left-sided abdominal distention. Enhanced computed tomography and magnetic resonance imaging revealed a unilocular cystic lesion measuring approximately 10 cm located in the left side of the abdomen. $^{18}$F-fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) revealed mottled mild FDG uptake in the cyst wall and intense FDG uptake in several mural nodules. The cystic mass with the descending colon was completely removed. Pathological examination of the specimens revealed various histologic patterns of adenocarcinoma, including mucin production in the mural nodules. We eventually diagnosed a primary cystadenocarcinoma arising from the mesentery of the descending colon.

Conclusions: Malignancy should be suspected in mesenteric or retroperitoneal cystic tumors with high FDG uptake, and complete resection should be performed with adequate margins.

Keywords: Mesenteric cyst, Cystadenoma, Cystadenocarcinoma, Mesentery, Mesocolon, PET, PET/CT

Background

Mesenteric cysts are relatively rare and have various histological forms [1–3]. Mesenteric cysts include mesenteric cystadenomas, borderline cystic neoplasms, and mesenteric cystadenocarcinomas that are similar to ovarian tumors [3–5]. Since primary cystadenocarcinoma is extremely rare, the differences in clinical and radiological features among benign, borderline, and malignant lesions are unclear [4]. Here, we present a case of mesenteric cystadenocarcinoma suspected to be a malignant tumor based on preoperative positron-emission tomography/computed tomography (PET/CT) findings.

Case presentation

A 50-year-old Japanese woman presented to a hospital with left-sided abdominal distention. Abdominal ultrasonography revealed a cystic mass in the left-lower quadrant of the abdomen measuring approximately 10 cm in diameter. The patient had a history of iron deficiency anemia due to menorrhagia. She was referred to our hospital for surgical management. Upon admission, she complained of left-sided abdominal
distention and denied abdominal pain and nausea. Physical examination revealed mild distention and a mildly tender mass in the left-lower quadrant of the abdomen. Laboratory examination findings on admission revealed elevated serum tumor marker levels: carcinoembryonic antigen (CEA) level of 21.4 ng/mL (normal range: 0–5.0) and carbohydrate antigen 19-9 (CA19-9) level of 804.0 U/mL (normal range: 0–37.0). Other laboratory results were normal except for a low hemoglobin level of 10.4 g/dL. Abdominal US revealed a tumor located in the left abdomen with a maximum diameter of about 9 cm. The cyst wall was about 4 mm thick and relatively uniform, with no septa or nodules visible within the cyst. Enhanced computed tomography (CT) and magnetic resonance imaging (MRI) of the abdomen revealed a 10.2 × 9.1 × 9.3-cm-sized unilocular cystic lesion with maximum 12-mm-sized nodules located on the left side of the abdomen (Fig. 1a–d). CT revealed three uniform contrast-enhanced nodules similar to the cyst wall. The boundary between the nodule and the wall was unclear for all three nodules; one of the nodules was seen as a gentle ridge. MRI revealed three nodules in the cyst, and the nodules and cyst wall showed low signal intensity on T1-weighted images and high signal intensity on T2-weighted images. The cystic mass was close to the left ureter, proximal jejunum, and descending colon, but separated from the left kidney and pancreas. The cyst wall was 3-mm thick. 18F-fluorodeoxyglucose (FDG)-PET/CT revealed mottled mild FDG uptake in the whole cyst wall and intense FDG uptake in the mural nodules with standardized uptake value (SUV-max) of 16.15, and no abnormal FDG uptake in other organs (Fig. 2). There were no malignant tumors on endoscopic gastrointestinal examination, and no findings to suspect gynecological diseases such as ovarian tumors. Although we were not able to identify the exact origin of the cyst based on radiological findings alone, we suspected a primary malignant cystic tumor arising from the retroperitoneum.

A midline laparotomy was performed after confirming the absence of disseminated lesions by laparoscopy and it revealed a cystic mass located in the
mesentery of the descending colon (Fig. 3). The cystic mass was rigidly attached to the descending colon, but not adhered to any other organs. The arterial supply of the tumor originated from the left colic artery; based on this, we diagnosed a mesenteric cystic tumor rather than a retroperitoneal cystic tumor. The cystic mass with the descending colon were completely removed without rupture.

The surgical specimen measured $9.2 \times 9.2 \times 6.5$ cm (Fig. 4a, b). The cyst contained a serous, cloudy, ‘café-au-lait-like’ fluid (Fig. 4c). The pathological diagnosis of the specimen was adenocarcinoma. However, it was difficult to determine the histopathological subtypes (mucinous, serous, or seromucinous) due to the atypical histologic findings. The inner surface of the cyst wall was lined predominantly by a single layer to multiple layers of columnar epithelium (Fig. 5a) and partially by simple cuboidal epithelium. The nodules consisted of atypical cells that showed nuclear atypia and abundant clear or eosinophilic cytoplasm composed of an irregular glandular or sheet-like structure with stromal infiltration (Fig. 5b, c), and the surface was covered with papillovillous component (Fig. 5d). The mesenteric tumor slightly invaded the subserosal layer of the descending colon, but not the mucosal layer. No ovarian stroma or teratomatous elements, including ectopic endometriosis, were observed. The atypical cells were immunohistochemically reactive for cytokeratin 7 (CK7), and p53, but negative for cytokeratin 20 (CK20), estrogen receptor (ER), progesterone receptor (PgR), Wilms’ tumor gene-1, napsin A, and calretinin. Therefore, the final diagnosis was primary cystadenocarcinoma arising from the mesentery of the descending colon; the atypical cells were immunohistochemically reactive for CEA and CA19-9 (Fig. 6a, b).

The postoperative course was uneventful, and the patient was discharged 11 days after the surgery. Adjuvant chemotherapy was initiated with S-1 (TS-1; tegafur, gimeracil, and oteracil potassium) at 100 mg/kg body weight per day for 8 courses (4 weeks of administration and 2 weeks of discontinuation). Approximately 1 year after the surgery, abdominal CT revealed no signs of disease recurrence, and serum CEA and CA19-9 levels had returned to normal.

**Discussion**

Mesenteric cysts are lesions that occur in or near the mesentery; they are not parasitic or dermoid and are not derived from normally placed retroperitoneal organs [6]. Mesenteric cysts are rare, with an incidence of 1/27,000 to 1/250,000 [7]. Among mesenteric cysts, primary cystadenocarcinoma is extremely rare, and therefore the clinical features of benign, borderline, and malignant primary cystadenomas are unclear and have not been fully differentiated [4]. Furthermore, it has been reported that the preoperative diagnosis for benign or malignant mesenteric cyst by routine imaging modalities is difficult, and the usefulness of PET/CT for this purpose is not well understood [1].

Thus, we performed a search of studies published in English between 1933 and August 2020 and reviewed the clinicopathologic features of cystadenomas, borderline malignant cystic neoplasms, and cystadenocarcinomas. Cases of retroperitoneal cysts and adenocarcinomas...
without cystic lesions were excluded. After excluding cases with insufficient information, a total of 14 cases
of primary benign cystic neoplasms (cystadenomas) and 6 cases of borderline malignant cystic neoplasms were
identified [3, 5, 8–23]. We also identified 9 cases of primary cystadenocarcinoma of the mesentery, including
the current case (Table 1) [4, 6, 24–29].

The median ages of patients with benign cystadenoma,
borderline malignant cystic neoplasm, and cystadenocar-
cinoma of the mesentery were 43 (14–80) years, 38 (32–
54) years, and 41 years (23–72 years), respectively. There
was no significant difference in age between patients
with benign and malignant tumors. These tumors were
more common in women, and only 3 cases have been
reported in men [16, 22, 29]. Regarding the subtype of
the final diagnosis, benign cystadenoma and borderline
cystic neoplasm were all mucinous. On the other hand,
cystadenocarcinoma was mucinous in 3 cases, serous in
2 cases, and seromucinous in 1 case. In the current case,
mucin-producing cells were primarily present in the cyst
wall and in the adenocarcinoma; however, the cyst wall
was partially contained in serous-like cuboidal cells. The
morphology of the ductal structure was diverse. Thus, it
was difficult to diagnose mucinous, serous or seromu-
cinous adenocarcinoma, and the diagnosis was only
cystadenocarcinoma.

Regarding preoperative imaging modality, in our litera-
ture review, US was more frequently used before 2000,
whereas CT was used more frequently than after 2000,
and MRI findings are gradually being reported. CT and
MRI can confirm the positional relationship between
the cystic tumor and adjacent organs, which is useful for
estimating the origin. Although it has been speculated
that the amount of soft tissue and internal septations
may suggest malignancy, as with cystic tumors of the
ovary, in this review, there were only two cases each with
solid components in cystadenoma and cystadenocar-
cinoma. There were no reports containing information
on internal septation [30, 31]. To the best of our knowl-
edge, there are no typical findings indicative of malignant
mesenteric tumors; none of the cases had a preoperative
diagnosis of mesenteric cystic neoplasm based on radi-
ological imaging. Knezevic et al. reported that retroperi-
toneal cysts had no specific radiological features, which

![Fig. 4 Gross findings. a Split findings of the resected specimens revealing that the tumor was an unilocular cystic mass, and the cyst wall had uneven wall thickness and had some raised nodules (red arrowheads). b The findings of the resected specimens revealed no obvious tumor in the mucosa of the descending colon. c The cyst component contained a serous cloudy café-au-lait-like fluid](image)
made obtaining an accurate preoperative diagnosis with standard imaging modalities nearly impossible [29]. Preoperative differential diagnosis may also be difficult for mesenteric cysts that have the same developmental origin as retroperitoneal cysts and are grouped into a single entity.

Fig. 5  Histopathological findings.  

- a: Microscopic findings (hematoxylin and eosin staining; magnification, ×400) reveal a cyst wall mainly lined with mucinous columnar epithelium.
- b–d: In the nodule, there were various histologic patterns of adenocarcinoma including irregular glandular, sheet-like structures, and the surface was covered with papillovillous component. The microscope magnification is ×20 in b, ×100 in c, and ×100 in d.

Fig. 6  Immunohistochemical images with staining of CEA and CA19-9.  

- a: Immunohistochemical images with staining of CEA (magnification, ×400) revealed overexpression of CEA was detected inside the carcinoma cell of the mesenteric cystadenocarcinoma.
- b: Immunohistochemical images with staining of CA19-9 (magnification, ×400) revealed CA19-9 was detected mainly on cell membranes of the carcinoma. Representative image was in the mural nodule.
Table 1 Summary of clinicopathological features of cystic neoplasm cases of the mesentery

| Characteristics                              | Cystadenoma n = 14 | Borderline malignant cystic neoplasm n = 6 | Cystadenocarcinoma of the mesentery n = 9 |
|----------------------------------------------|---------------------|---------------------------------------------|------------------------------------------|
| **Sex**                                      |                     |                                             |                                          |
| Female                                       | 12                  | 5                                           | 8                                        |
| Male                                         | 1                   | 1                                           | 1                                        |
| **Age (years)**                              |                     |                                             |                                          |
| Median                                       | 43 (14–80)          | 38 (32–54)                                  | 41 (23–72)                               |
| **Symptoms and signs (including duplicate)** |                     |                                             |                                          |
| Incidental finding                          | 5                   | 0                                           | 1                                        |
| Abdominal pain/back pain                    | 4                   | 3                                           | 3                                        |
| Abdominal distention/discomfort             | 4                   | 5                                           | 2                                        |
| Nausea/vomiting                             | 0                   | 2                                           | 1                                        |
| Weight loss                                  | 0                   | 0                                           | 2                                        |
| Not described                                | 2                   | 1                                           | 0                                        |
| **Preoperative imaging modality (including duplicate)** |                     |                                             |                                          |
| US                                           | 2                   | 4                                           | 3                                        |
| CT                                           | 7                   | 4                                           | 7                                        |
| MRI                                          | 7                   | 2                                           | 1                                        |
| PET/CT                                       | 0                   | 0                                           | 1                                        |
| Not described                                | 2                   | –                                           | –                                        |
| **Tumor location**                           |                     |                                             |                                          |
| Appendix                                     | 1                   | 0                                           | 0                                        |
| Ascending colon                              | 1                   | 1                                           | 1                                        |
| Transverse colon                             | 1                   | 0                                           | 3                                        |
| Descending colon                             | 2                   | 2                                           | 3                                        |
| Sigmoid colon                                | 4                   | 1                                           | 2                                        |
| Sigmoid and descending colon                 | 0                   | 1                                           | 0                                        |
| Small intestine                              | 3                   | 0                                           | 0                                        |
| Mesentery (not described)                    | 2                   | 1                                           | 0                                        |
| **Tumor size (Maximum diameter: cm)**        |                     |                                             |                                          |
| Median                                       | 12 (7–40)           | 17 (10–25)                                  | 10 (5–18)                                |
| **Internal structure**                       |                     |                                             |                                          |
| Unilocular                                    | 3                   | 2                                           | 2                                        |
| Multilocular                                  | 4                   | 2                                           | 2                                        |
| Not described                                | 7                   | 2                                           | 5                                        |
| **Surgical treatment**                       |                     |                                             |                                          |
| Only cystectomy                              | 6                   | 1                                           | 3                                        |
| Cystectomy with bowel resected               | 5                   | 1                                           | 3                                        |
| Cystectomy with combined resection involving other organs | 1                   | 1                                           | 1                                        |
| Cytoreductive surgery                        | 0                   | 0                                           | 1                                        |
| Unresectable                                 | 0                   | 0                                           | 1                                        |
| Not described                                | 2                   | 3                                           | 0                                        |
| **Subtype of final diagnosis**               |                     |                                             |                                          |
| Mucinous                                     | 14                  | 6                                           | 3                                        |
| Serous                                       | 0                   | 0                                           | 2                                        |
| Seromucinous                                 | 0                   | 0                                           | 1                                        |
| Indistinguishable                            | 0                   | 0                                           | 3                                        |
In the current case, we considered the possibility of a malignant cystic tumor based on the high serum tumor marker levels and high uptake of FDG in mural nodules on FDG-PET/CT. FDG-PET/CT provides important physiologic information on altered tissue metabolism that forms the basis for detection and diagnosis of carcinoma. Compared to normal cells, malignant cells develop significant alterations in carbohydrate metabolism [32]. Additionally, PET/CT is useful for staging, optimizing treatment, restaging, therapy monitoring, and prognostication of various types of malignant tumors [33]. To our knowledge, there are no reports of the use of PET/CT for mesenteric cystadenocarcinoma. Furthermore, only a few cases on the use of FDG-PET/CT for evaluation of retroperitoneal tumors have been reported to date, with 2 cases of benign mesenteric cysts, 1 case of a retroperitoneal cystadenocarcinoma, and 1 case of retroperitoneal cystic tumor [33–36]. The morphology of pancreatic cystic tumor and ovarian tumors is similar to that of cystadenoma and cystadenocarcinoma. Sperti et al. demonstrated the importance of FDG accumulation in identifying malignant cystic tumors of the pancreas [37]. Approximately 94% of malignant cystic tumors showed FDG uptake with SUV of 2.6 to 12.0; only 1 in 39 cases of mucinous cystadenoma showed increased SUV of 2.6. The sensitivity, specificity, and positive and negative predictive values for FDG-PET/CT in detecting malignant tumors were 94%, 97%, 94%, and 97%, respectively. Although the study did not mention the relationship between the site of accumulation and the tumor, high SUV in cystic tumor may be highly indicative of carcinoma. However, it should be kept in mind that FDG not only accumulates in well-metabolized tumors like carcinoma, but also in inflammatory areas [38, 39]. In the current case, there were no inflammatory findings, including cystic tumor, detected preoperatively. We were able to make one-on-one comparison between the uptake areas in PET/CT and the pathological findings. The FDG accumulation site contained more adenocarcinoma than other areas, highly suggesting that the site of FDG accumulation was not due to inflammation but as a result of adenocarcinoma. If FDG-PET/CT reveals high FDG uptake in the absence of inflammatory findings, the possibility of malignancy should be considered and appropriate treatment should be initiated [33–36]. It is difficult to distinguish benign from malignant tumors using standard radiological imaging such as CT, MRI, and US. In comparison, FDG-PET/CT may be useful in differentiating mesenteric cystic neoplasm, since in the current case, FDG accumulation was witnessed in adenocarcinoma.

The recommended treatment for cystadenomas is surgical resection to obtain a histopathological diagnosis and manage tumor-related symptoms [4, 28, 40]. There have been no cases of lymph node metastasis from mesenteric cystadenocarcinoma; postoperative local recurrence, peritoneal dissemination recurrence, and even benign peritoneal pseudomyxoma have been reported [28, 40]. Therefore, although there is no evidence for active lymph node dissection, complete resection with adequate margin to prevent local recurrence or pseudomyxoma recurrence should be undertaken. Although there is inadequate evidence regarding the use of adjuvant chemotherapy for mesenteric cystadenocarcinoma, we decided on oral administration of S-1, considering the risk of recurrence. S-1 is considered to be highly versatile and is indicated for adenocarcinomas in various organs, including gastrointestinal cancers [41, 42].

Conclusions
We report the first case of primary cystadenocarcinoma of the mesentery in which FDG-PET/CT was performed preoperatively. If high FDG is accumulated in the mesenteric or retroperitoneal cystic tumor, we should consider the possibility of malignancy and perform complete resection with adequate margins.

Abbreviations
PET/CT: Positron emission tomography/computed tomography; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; CT: Computed tomography; MRI: Magnetic resonance imaging; FDG: 18F-fluorodeoxyglucose; SUV: Standardized uptake value; CK7: Cytokeratin 7; CK20: Cytokeratin 20; ER: Estrogen receptor; PgR: Progesterone receptor.

Acknowledgements
We thank all staff members employed at Kagoshima University Hospital for treating and caring for the patient.

Authors’ contributions
YH and YM drafted the manuscript. HK, KT, TI, YK, SI, PN, TA, KM, HS and SN managed the perioperative course and collected the data. HN and AT contributed to the pathological study. TO supervised the writing of the manuscript. All authors discussed the content of the manuscript. All authors read and approved the final manuscript.

Funding
We declare that each author received no funding for this study.

Availability of data and materials
The datasets supporting the conclusions of this article are included within the article and its additional files.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima 890-8520, Japan. 2 Department of Pathology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima 890-8520, Japan.
School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. 2 Department of Health Sciences, School of Medicine, Kagoshima University, Kagoshima, Japan.

Received: 28 September 2020  Accepted: 23 November 2020
Published online: 04 December 2020

References
1. de Perrot M, Bründler M, Tätzsch M, Mentha G, Morel P. Mesenteric cysts. Toward less confusion? Deg Surg. 2000;17:325–8.
2. Ros PR, Olmsted WW, Moser RP Jr, Dachman AH, Hjermstad BH, Sobin LH. Mesenteric and omental cysts: histologic classification with imaging correlation. Radiology. 1987;164:327–32.
3. Metaxas G, Tangalos A, Pappa P, Papageorgiou I. Mucinous cystic neoplasms of the mesentery: a case report and review of the literature. World J Surg Oncol. 2009;7:42.
4. Sobnach S, Klopwers K, Burmeister S, Locketz M, Roodt L, Thomson SR, et al. Primary seromucinous cystadenocarcinoma of the mesentery. S Afr J Surg. 2016;54:42.
5. Talwar A, Bell NJ, Nicholas D. Mucinous cystadenoma of colonic mesentery: report of a case. Dis Colon Rectum. 2004;47:1412–4.
6. Bury TF, Picollo VE. Malignant transformation of benign mesenteric cyst. Am J Gastroenterol. 1994;89:2085–7.
7. Kurtz RJ, Heimann TM, Holt J, Beck AR. Mesenteric and retroperitoneal cysts. Ann Surg. 1986;203:109–12.
8. Banerjee R, Gough J. Cystic mucinous tumours of the mesentery and retroperitoneum: report of three cases. Histopathology. 1988;12:277–32.
9. Cohen I, Altaras M, Lew S, Jaffie R, Ben-Aderet N. Huge mesenteric mucinous cystadenoma in normal pregnancy. Obstet Gynecol. 1988;71:1030–2.
10. McEvoy AW, Cahill CJ, Jameson C. Mucinous cystadenoma of the sigmoid mesocolon: a previously unreported abdominal tumour. Eur J Surg Oncol. 1997;23:88–90.
11. Felemban A, Tulandi T. Laparoscopic excision of a mesenteric cyst diagnosed preoperatively as an ovarian cyst. J Am Assoc Gynecol Laparosc. 2000;7:429–31.
12. Czubalski A, Barwijk A, Radzikiewicz G (Large mucinous cyst in a patient suspected of ovarian cyst). Ginekol Pol. 2004;75:545–7.
13. Potoka D, McClain R, Upperman JS. Pediatric cystadenoma of the mesocolon showing features of malignancy. Case Rep Surg. 2012;2012:727105.
14. Shiono S, Suda K, Nobukawa B, Arakawa A, Yamasaki S, Sasahara N, et al. Pancreatic, hepatic, splenic, and mesenteric mucinous cystic neoplasms (MCN) are lumped together as extra ovarian MCN. Pathol Int. 2006;56:71–7.
15. Del Gobbo A, Bimbatti M, Ferrero S. A case report of mesenteric mucinous cystadenocarcinoma with review of the literature. BMC Gastroenterol. 2010;10:35.
16. Cauchy F, Lefevre JH, Mourra N, Parc Y, Tiret E, Balladur P. Mucinous cystadenoma arising from sigmoid mesocolon. J Surg Case Rep. 2012;2012:727105.
17. Mistry K, Penna M, Dindyal S, Mukhtar H. A mucinous cystic neoplasm of the mesocolon showing features of malignancy. Case Rep Surg. 2012;2012:656420.
18. Tan A, Li R, Rafique M, Qin S, Pharm T. A rare case of giant extra-ovarian mucinous cystadenoma arising from sigmoid mesocolon. J Surg Case Rep. 2018;2018:ry038.
19. Lambert RG, Cervantes BYH, Gonzalez MR, Lopez DM, Edwin F. Large intra-abdominal mucinous cystic adenoma: is it of ovarian or mesenteric origin. Pan Afr Med J. 2020;36:122.
20. Vrettos ME, Kostopoulos E, Papavasileiou C, Sikas N, Agelidou S. A mucinous tumor of the mesocolon with features of borderline malignancy. Surg Endosc. 2000;14:595.
21. Mourra N, Werbrouck A, Arrive L. A large intra-abdominal cystic mass arising from the mesocolon. Diagnosis: Mucinous cystadenoma of the mesocolon with high-grade dysplasia. Gastroenterology. 2011;141(1):534.
22. Madakshira MG, Salika UN. Primary borderline mucinous cystadenoma of the mesentery. Indian J Cancer. 2018;55:306–7.
23. Barani T, Goteva M,-polon A, Nath R, Mehrz G, Lane G, et al. A giant mucinous borderline neoplasm of the mesentery misdiagnosed as an adrenal cyst – a case report and literature review. Clinical Obstetrics: Gynecology and Reproductive Medicine; 2017. p. 3.
24. Ew P. Transactions of the New York Surgical Society-Stated Meetings March 9, 1932. Ann Surg. 1933;97:114–27.
25. Tykkä H, Koivuniemi A. Carcinoma arising in a mesenteric cyst. Am J Surg. 1975;129:709–11.
26. Linden PA, Ashley SW. Mucinous cystadenocarcinoma of the mesentery. Surgery. 2000;127:707–8.
27. McCoubrey A, Houghton O, McCallion K, McCluggage WG. Serous cystadenocarcinoma of the sigmoid mesentery arising in cystic endosalpingiosis. J Clin Pathol. 2005;58:1221–1.
28. Nelson J, Deneve J, Dickson P, Sylvestre P, Munene G. Management of a ruptured mucinous mesenteric cyst with hyperthermic intraperitoneal chemotherapy. Tumori. 2014;100:e55–8.
29. Obuchi T, Shimooki O, Sasaki A, Abe T, Wakabayashi G. Serous cystadenocarcinoma of the mesentery in a man: case report and review of literature. Gastroenterol Rep (Oxf). 2014;2:306–10.
30. Flicek KT, VanBuren W, Dudiak K, Lahkman Y, Chen UW, Butler K, et al. Borderline epithelial ovarian tumors: what the radiologist should know. Abdom Radiol (NY). 2020. https://doi.org/10.1007/s00261-020-02688-z.
31. Mayr D, Hirschmann A, Lohm U, Diebold J. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline line tumors and extraovarian implants. Gynecol Oncol. 2006;103:883–7.
32. Bar-Shalom R, Valdivia AY, Blaufux MD. PET imaging in oncology. Semin Nucl Med. 2000;30:150–85.
33. Kitajima K, Kono A, Konishi J, Suenaga Y, Takahashi S, Sugimura K. 18F-FDG-PET/CT findings of retroperitoneal tumors: a pictorial essay. Jpn J Radiol. 2013;31:301–9.
34. Dong A, Zhai Z, Wang Y, Zuo C, MRI, enhanced CT, and FDG PET/CT in primary retroperitoneal mucinous cystadenocarcinoma. Clin Nucl Med. 2015;40:50–3.
35. McMahan MA, Kerr J, O’Connell MJ. Mesenteric inclusion cyst: appearance at PET/CT. Clin Nucl Med. 2008;33:434–5.
36. Tanioka N, Maeda H, Tsuda S, Iwabu J, Namikawa T, Iguchi M, et al. A case of spontaneous mesenteric hematoma with diagnostic difficulty. Surg Case Rep. 2020;6:124.
37. Sperti C, Pasquali C, Chierichetti F, Liessi G, Ferlin G, Pedrazzoli S. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas. Ann Surg. 2001;234:675–80.
38. Kresnik E, Gallowitsch HJ, Mikosch P, Würzt F, Alberer D, Hebenstreit A, et al. (18)F-FDG positron emission tomography in the early diagnosis of enterocolitis: preliminary results. Eur J Nucl Med Mol Imaging. 2002;29:1389–92.
39. Evidence-based indications for the use of PET-CT in the United Kingdom 2016. Clin Radiol. 2016;71:e171–88.
40. Zappa L, Sugarbaker PH. Mesenteric cyst: report of a case-resulting in pseudomyxoma peritonei. Tumori. 2010;96:322–3.
41. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.
42. Yoshida M, Ishiguro M, Ikejiri K, Mochizuki I, Nakamoto Y, Kinugasa Y, et al. S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial). Ann Oncol. 2014;25:1743–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.